A measured, practical case for broader participation in women’s health.
This is a careful discussion of menopause, access, and the part men can play in making women’s health feel less closed off and less easily dismissed.

EMJ
322 episodes listed below
PRESS PLAY
Join the EMJ GOLD team for a weekly exploration of all things pharma, featuring thought-provoking conversations, insightful interviews with high-profile industry guests and discussions about the latest trends and innovations taking the pharmaceutical sphere by storm. Whether its marketing, medical affairs, the use of digital techniques to create patient-centric approaches or something in between, there's something here for anyone interested in the pharmaceutical industry.
Based on 6 episodes we listened to · September 2026
Senior pharma leaders make the industry's operating choices, communication challenges and scientific transitions easier to understand.
EMJ GOLD builds its conversations around the decisions shaping pharmaceutical work, from customer engagement and scientific communication to leadership and drug development.
A 25 percent email open rate comes up; your pharma marketing brain finally has company.
Press play if you want
Short reviews from the PlayNext desk, based on the episodes we processed.
A measured, practical case for broader participation in women’s health.
This is a careful discussion of menopause, access, and the part men can play in making women’s health feel less closed off and less easily dismissed.
A calm, clinically grounded look at screening, density, and patient awareness in breast cancer care.
This episode takes a practical, patient-focused look at breast cancer screening. It works best when it ties clinical detail to the everyday challenge of dense breast tissue, which can make mammography less sensitive and allow cancers to be missed, so supplemental screening…
A concise year-end look at healthcare and life sciences, balancing pressure, progress, and collaboration.
EMJ Gold closes 2025 with a compact year-end look at healthcare and life sciences, moving through progress, pressure, reflection, and recalibration.
A clear look at how diagnostic bias and trial design shape patient outcomes.
This piece treats diagnostic bias as a concrete problem rather than an abstract one: when diagnosis goes off course, treatment tends to follow it.
A measured look at COPD, where patient care, judgement, and environmental responsibility meet.
The episode treats COPD as both a clinical problem and a systems one, moving from patient care to the wider burden on health services and the planet.
A measured look at UK medicine access through NHS capacity, ageing, obesity, and prevention.
Richard Maughan, Senior Director and Head of UK Policy and Public Affairs at Pfizer, grounds the episode in a simple question: how the UK can improve access to medicines while the healthcare system is under strain.
A steady look at how pharma teams decide when to persist, pivot, or stop.
This episode treats pharma R&D as a sequence of hard calls: when to keep going, when to pivot, and when to stop. Christoph von der Goltz brings experience from more than 15 years in pharma R&D and board-certified psychiatry, and the conversation is strongest when it gets…
A grounded look at omnichannel that favors practical questions over buzzwords.
S10 E02 treats omnichannel as a working problem, not a slogan. Yasin Marzoufi comes across as a global omnichannel engagement lead who is focused on making the customer journey smoother and getting content where it needs to go.

Healthcare markets without the gloss.

Digital health, measured against real operations.
Healthcare value, stripped of polite fiction.

Women changing healthcare, one conversation at a time.

Healthcare strategy, translated into operational consequence.

Business fluency for anesthesia careers.
This episode features an interview with Matt Mortimer-Ryan from GSK, discussing patient-centric pharma marketing and using behavioral insights to drive campaigns.
This episode marks Blood Donation Week and World Blood Donor Day with a conversation about how haematology has changed over the last decade.
This season finale of EMJ GOLD curates standout insights from pharma leaders, covering topics like self-advocacy, women's health awareness gaps, COPD diagnosis challenges, content overload in marketing, and access disparities in medicine.
Isabel O'Brien closes out the year with a reflective wrap-up of 2025 across healthcare and life sciences.
Aja speaks with Dr Joanna Rees about breast cancer screening, imaging, and the promise of AI.
Rebecca Vermeulen, VP at Genentech and HBA Star award winner, discusses her 30-year career journey focused on patient centricity, her leadership philosophy of 'leading with love', and pressing issues in women's health disparities.
In this season finale, Denise Broderick, President and Managing Director of Galen, shares her journey from academia to pharma leadership, discussing her decision-making philosophy, the importance of kindness in business, and her advice for women aspiring to lead in the industry.
Richard Maughan starts with access.
Host Isabelle O'Brien interviews pharmaceutical professional Carol about gender disparities in healthcare, focusing on underrepresentation of women in clinical trials, male bias in preclinical research, and how diversifying pharma leadership could improve drug development.
EMJ Gold host Isabel interviews Rob Stewart, CEO of women's health pharma company Theramex, about men's role in advancing women's healthcare.
EMJ Gold opens season 10 with Isabel speaking to Deepa Chari, Vice President and Head of Global Scientific Communications at GSK, about how scientific communication has moved from publications to digital dissemination.
Dr Dejan Adiboye joins EMJ Gold to talk about support, leadership, and how cancer care keeps changing.
An interview with a Medtronic representative exploring the history, current applications, and future of ECMO (Extracorporeal Membrane Oxygenation) technology.
Christoph von der Goltz discusses the high failure rates in psychiatric drug development, explaining the challenges of subjective endpoints and placebo effects.
An interview with a pharmaceutical executive from Theramex about the historical exclusion of women from clinical trials and the changes needed to prioritize women's health.
Host Isabel O'Brien interviews expert Carol about systemic gender bias in healthcare, focusing on how women face delayed diagnoses across conditions like Parkinson's and lupus, and how historic exclusion from clinical trials affects modern drug safety and efficacy.
It opens with a direct introduction to Yasin Marzoufi and the idea of disrupting omnichannel.
EMJ Gold host Isabel interviews Shish Patel, Medical Director at Chiesi UK, about the underdiagnosis and burden of COPD, its mental health impacts, and the significant environmental footprint of respiratory care.
A discussion on gender disparities in cardiovascular clinical trials, focusing on women's participation and symptom presentation.
Industry experts discuss key uncertainties shaping pharmaceutical decisions in 2026, including political environment, AI regulation, and pricing policy.
The EMJ GOLD podcast kicks off 2026 with industry leaders discussing opportunities, threats, and unknowns in pharma and life sciences.
An interview discussing gender inequities in healthcare, including diagnostic bias and representation in clinical trials.
An interview discussing the future of Alzheimer's disease research and innovations in neuroscience.
An interview with Elias Ravonta, founder of Orcason Medical, discussing his journey, innovative point-of-care devices to combat AMR, and tips for startups.
Interview with Nedim Pipic from Boehringer Ingelheim about improving outcomes for serious mental illnesses and pharma's role.
Season finale of EMJ GOLD podcast featuring an interview with Dr.
The hosts introduce a special episode featuring an interview with Stefan Voxen, SVP at AstraZeneca, discussing his career and the pharmaceutical industry.
Host Jade Williams interviews Christy Siegel, general manager at Novartis, about her role in breast and women's cancers and the pharmaceutical industry.